GRAIL Q1 2026: Galleri Volume Surges 50%, Revenue Up 37%, but Path to Profitability Remains Distant

What happened

GRAIL reported Q1 2026 Galleri revenue of $39.8M (up 37% YoY) on test volume exceeding 56,000 (up 50% YoY), reflecting continued strong adoption. The company also announced plans to integrate Galleri into the Epic EHR platform, which could broaden provider access. However, operating losses remain substantial—the prior quarter's (Q3 2025) operating loss was $125M on $36M revenue—and no improvement in ASPs or cost structure was disclosed. Upcoming ASCO 2026 data from NHS-Galleri and PATHFINDER-2 trials may further inform the PMA pathway, but regulatory and reimbursement catalysts remain binary and unresolved. Meanwhile, cash burn is trending toward the $325M target, but the company is far from self-sustaining, and competition from Exact Sciences and Freenome continues.

Implication

GRAIL's Q1 results reinforce the volume growth trajectory that underpins the HOLD thesis, but do not fundamentally alter the binary nature of the key value drivers. The 50% test volume increase and planned EHR integration are operational wins, but revenue growth is still outpaced by operating losses, and average selling prices likely remain under pressure. With PMA approval expected in 2026 and an unsettled LDT regulatory landscape, we see no compelling reason to upgrade to BUY; continued execution on volume is already priced in. The upcoming ASCO presentations could be a near-term catalyst if data are positive, but until gross margins and reimbursement improve, the stock remains a show-me story. Thus we maintain our HOLD rating with a neutral outlook.

Thesis delta

Prior thesis anticipated volume growth but flagged binary PMA/reimbursement risks. Q1 volume and revenue growth exceeded expectations (50% volume vs 39% in Q3 2025), and the Epic integration could enhance future access. However, the lack of any improvement in ASP or operating leverage means the core investment case remains unchanged: progress is tangible, but the pre-profitability stage and reliance on uncertain regulatory milestones persist.